CR9638A - Metodos para determinar las farmacocineticas de terapias dirigidas - Google Patents

Metodos para determinar las farmacocineticas de terapias dirigidas

Info

Publication number
CR9638A
CR9638A CR9638A CR9638A CR9638A CR 9638 A CR9638 A CR 9638A CR 9638 A CR9638 A CR 9638A CR 9638 A CR9638 A CR 9638A CR 9638 A CR9638 A CR 9638A
Authority
CR
Costa Rica
Prior art keywords
methods
pharmacocinetics
directed therapies
therapies
directed
Prior art date
Application number
CR9638A
Other languages
English (en)
Inventor
Nitkin K Damle
Kiran Khandke
Erwin R Boghaert
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9638A publication Critical patent/CR9638A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/55—Specular reflectivity
    • G01N21/552—Attenuated total reflection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/55—Specular reflectivity
    • G01N21/552—Attenuated total reflection
    • G01N21/553—Attenuated total reflection and using surface plasmons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a metodos para determinar las farmacocineticas de terapias objetivo usando tecnicas de deteccion de masa.
CR9638A 2005-07-01 2008-01-07 Metodos para determinar las farmacocineticas de terapias dirigidas CR9638A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69541905P 2005-07-01 2005-07-01

Publications (1)

Publication Number Publication Date
CR9638A true CR9638A (es) 2008-02-20

Family

ID=37103061

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9638A CR9638A (es) 2005-07-01 2008-01-07 Metodos para determinar las farmacocineticas de terapias dirigidas

Country Status (14)

Country Link
US (1) US20070003559A1 (es)
EP (1) EP1899731A1 (es)
JP (1) JP2009500623A (es)
KR (1) KR20080026206A (es)
CN (1) CN101253408A (es)
AU (1) AU2006265857A1 (es)
BR (1) BRPI0613694A2 (es)
CA (1) CA2613880A1 (es)
CR (1) CR9638A (es)
EC (1) ECSP088146A (es)
IL (1) IL188450A0 (es)
NO (1) NO20080216L (es)
RU (1) RU2007149180A (es)
WO (1) WO2007005690A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008150261A1 (en) * 2007-06-04 2008-12-11 Wyeth Detection and quantitation of calicheamicin
WO2010082497A1 (ja) * 2009-01-15 2010-07-22 株式会社アルバック タンパク質系薬剤の体内濃度の測定方法
CN102977189B (zh) * 2012-12-10 2014-04-16 首都医科大学附属北京朝阳医院 一种结合fap的多肽
CN114112980B (zh) * 2022-01-24 2022-05-10 武汉宏韧生物医药股份有限公司 一种基于数据分析的药物组分检测方法与系统

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4970198A (en) * 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5037651A (en) * 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5108912A (en) * 1987-01-30 1992-04-28 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) * 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) * 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9212416D0 (en) * 1992-06-11 1992-07-22 Medical Res Council Reversible binding substances
SE9201984D0 (sv) * 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
GB9518429D0 (en) * 1995-09-08 1995-11-08 Pharmacia Biosensor A rapid method for providing kinetic and structural data in molecular interaction analysis
SE9504046D0 (sv) * 1995-11-14 1995-11-14 Pharmacia Ab Method of determining affinity and kinetic properties
US5952329A (en) * 1996-01-23 1999-09-14 The General Hospital Corporation Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
JPH10221249A (ja) * 1996-12-05 1998-08-21 Norio Miura 薬物の測定装置とセンサ及び該センサに用いる検出素子
SE9604575D0 (sv) * 1996-12-12 1996-12-12 Biacore Ab Method and system for analyte determination
ATE295541T1 (de) * 1999-06-18 2005-05-15 Biacore Ab Verfahren und vorrichtung zur untersuchung von wirksstoffskandidaten und zur bestimmung ihrer pharmakokinetischen parametern
US7171879B2 (en) * 2001-07-02 2007-02-06 Sd3, Llc Discrete proximity detection system
WO2001097844A1 (en) * 2000-06-22 2001-12-27 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
CA2445898A1 (en) * 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US20040186359A1 (en) * 2001-07-09 2004-09-23 Beaudoin Stephen P. Afinity biosensor for monitoring biological process
US6997863B2 (en) * 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
DK1507556T3 (en) * 2002-05-02 2016-09-12 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
EP1588162B1 (en) * 2003-01-03 2008-09-17 Aurelium Biopharma Inc. Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
JP2004251807A (ja) * 2003-02-21 2004-09-09 Nipro Corp エンドトキシン測定用センサ、測定方法、診断方法、製造方法およびセンサ再生方法
JP2005140590A (ja) * 2003-11-05 2005-06-02 Nipro Corp 表面プラズモン共鳴による生物学的試料測定用装置システム
BR122018071808B8 (pt) * 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado

Also Published As

Publication number Publication date
KR20080026206A (ko) 2008-03-24
ECSP088146A (es) 2008-02-20
BRPI0613694A2 (pt) 2011-01-25
EP1899731A1 (en) 2008-03-19
WO2007005690A1 (en) 2007-01-11
CN101253408A (zh) 2008-08-27
US20070003559A1 (en) 2007-01-04
JP2009500623A (ja) 2009-01-08
NO20080216L (no) 2008-02-27
RU2007149180A (ru) 2009-08-10
AU2006265857A1 (en) 2007-01-11
CA2613880A1 (en) 2007-01-11
IL188450A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
FIC20230027I1 (fi) Tremelimumabi
CY2019041I2 (el) Τροποποιημενα αντισωματα εναντι il-23
WO2007123791A3 (en) Methods of determining cellular chemosensitivity
FR15C0048I2 (fr) Anticorps antagonistes de il-17
DK1879623T3 (da) Genterapi til rygmarvssygdomme
DK1848718T3 (da) E1 aktiveringsenzymhæmmere
NO20076678L (no) Glutamataggrekanaseinhibitorer
DE502006008527D1 (de) Rohrtarget
DK1966388T3 (da) Tilsigte vektor-fosfolipidkonjugater
DK1951724T3 (da) Sammensmeltede bicykliske mTOR-inhibitorer
NO20075068L (no) Lipocalinprotein
DE602005022454D1 (de) Enzymatische nachweistechniken
DK3264094T3 (da) Fremgangsmåder til evaluering af en immunrespons på et terapeutisk middel
NL1032046A1 (nl) Prostaglandinederivaten.
SI1833995T1 (sl) Identifikacija tarč RNA z uporabo helikaz
FI20065708A0 (fi) Laitteisto yksillöllisesti muotoiltujen jalkineiden suunnittelemiseksi
CR9638A (es) Metodos para determinar las farmacocineticas de terapias dirigidas
NO20052035L (no) Stopemasse
DE502007000476D1 (de) Verbundlenkerachse
DK1876916T3 (da) Produkt
FR2894983B1 (fr) Test de caracterisation des anticorps.
RU2007123928A (ru) Способ профилирования донных отложений
AT502614A3 (de) Laser-goniometer
DE112006002949A5 (de) Laufschuh mit Stollen
WO2007117569A3 (en) Methods of determining skeletal maturity

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)